Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study
机构：[1]Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China[2]Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China[3]Guizhou Prov Peoples Hosp, Dept Ophthalmol, Guiyang, Guizhou, Peoples R China
Background To evaluate 5-year outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy and combination therapy of anti-VEGF agents and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) in a real-world Chinese population. Methods Retrospective study. Fifty-three eyes of 46 patients with subtype 1 and 2 PCV followed up for at least 60 months were grouped into three regimens: anti-VEGF monotherapy, PDT combining with anti-VEGF therapy initially, and PDT combining with deferred anti-VEGF therapy. Main outcome measure was best-corrected visual acuity (BCVA) using logarithm of minimal angle of resolution (logMAR). Results The mean BCVA of eyes with subtype 1 PCV (n = 28) deteriorated from 0.69 logMAR at baseline to 1.25 logMAR at months 60 (P = 0.001), while the mean BCVA of eyes with subtype 2 PCV (n = 25) sustained stable from 0.62 logMAR at baseline to 0.57 at months 60 (P = 0.654). No significant differences of visual outcomes were found between the 3 treatment regimens for subtype 1 PCV. Anti-VEGF monotherapy and initial combination treatment had better visual outcomes in eyes with subtype 2 PCV than deferred combination group during part of follow-up significantly. Initial combination group needed a less number of PDT than deferred combination group (P < 0.001). Conclusions Compared with subtype 1 PCV, subtype 2 PCV has a more favorable visual outcome in real world. All the regimens presented unfavorable visual outcomes for subtype 1 PCV. Anti-VEGF monotherapy and initial combination therapy should be superior to deferred combination therapy in the long-term management of subtype 2 PCV. Prospective randomized studies of larger size are needed to determine the long-term efficacy and safety of various treatment for PCV in real world.
基金：
National Natural Science Foundation of China (NSFC) [81670879]
基金编号：81670879
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|4 区医学
小类|4 区眼科学
最新[2023]版：
大类|4 区医学
小类|3 区眼科学
第一作者：
第一作者机构：[1]Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China[2]Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[1]Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China[*1]Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China[2]Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China[*2]Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Yang Jingyuan,Yuan Mingzhen,Wang Erqian,et al.Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study[J].BMC OPHTHALMOLOGY.2019,19(1):237.doi:10.1186/s12886-019-1245-4.
APA：
Yang, Jingyuan,Yuan, Mingzhen,Wang, Erqian,Xia, Song&Chen, Youxin.(2019).Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study.BMC OPHTHALMOLOGY,19,(1)
MLA：
Yang, Jingyuan,et al."Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study".BMC OPHTHALMOLOGY 19..1(2019)
